Long-term safety and efficacy of single-agent lbrutinib in patients with relapsed or refractory mantle cell lymphoma: Updated results of an international, multicenter, open-label phase 2 study Dreyling, M., Wang, M. L., Rule, S., Martin, P., Goy, A., Auer, R., Kahl, B. S., Jurczak, W., Advani, R. H., Romaguera, J. E., Williams, M. E., Barrientos, J. C., Chmielowska, E., Radford, J., Stilgenbauer, S., Jedrzejczak, W. W., Johnson, P., Spurgeon, S. E., Zhang, L., Baher, L., Cheng, M., Beaupre, D. M., Blum, K. A. KARGER. 2015: 18–19

View details for Web of Science ID 000364268800038